v3.26.3
Share-Based Payments (Tables)
 12 Months Ended
Jun. 30, 2026
Statements [Line Items]  
Summary of Total Expenses Arising From Share-based Payment Transactions
Total expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense were as follows:
 
     Consolidated  
     June 30, 2026
A$		      June 30, 2025
A$		  
Employee share-based payment expense
      1,589,774        1,163,543  
  
 
 
     
 
 
  
     1,589,774        1,163,543  
  
 
 
     
 
 
  
Executive Incentive Plan [member] | Performance rights [member]  
Statements [Line Items]  
Summaries of Performance Rights Granted
Fiscal year ended June 30, 2026
 
Grant date
    Fair
Value		      Balance at start of
the fiscal year
Number		      Granted during
the fiscal year
Number		      Exercised during
the fiscal year
Number		     Lapsed during
the fiscal year
Number		      Balance at end of
the fiscal year
Number		      Vested and
exercisable at
end of the fiscal
year Number		  
November 26, 2021
      0.490        1,200,000        —         (1,200,000 )      —         —         —   
November 26, 2021
      0.490        1,500,000        —         (1,500,000 )      —         —         —   
December 1, 2021
      0.290        966,666        —         (966,666 )      —         —         —   
December 16, 2022
      0.330        1,112,334        —         (1,112,334 )      —         —         —   
January 31, 2024
      0.350        258,064        —         (129,032 )      —         129,032        —   
November 22, 2024
      0.305        2,700,000        —         —        —         2,700,000        —   
November 22, 2024
      0.305        3,600,000        —         —        —         3,600,000        —   
November 22, 2024
      0.305        3,200,000        —         —        —         3,200,000        —   
December 5, 2024
      0.310        1,700,000        —         —        —         1,700,000        —   
October 13, 2025
      0.290        —         758,059        (92,935 )      —         665,124        —   
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
         16,237,064        758,059        (5,000,967 )      —         11,994,156        —   
Fiscal year ended June 30, 2025
 
Grant date
   
Fair
Value
     
Balance at start

of the fiscal year
Number
     
Granted
during the
fiscal year
Number
     
Exercised during
the fiscal year
Number
    
Lapsed
during the
fiscal year
Number
    
Balance at end
of the fiscal
year Number
     
Vested and
exercisable at

end of the

fiscal year
Number
  
November 26, 2021
      0.490        3,600,000        —         (2,400,000 )      —        1,200,000        —  
November 26, 2021
      0.490        4,500,000        —         (3,000,000 )      —        1,500,000        —  
December 1, 2021
      0.290        1,933,333        —         (966,667 )      —        966,666        —   
December 16, 2022
      0.330        1,112,334        —         —        —        1,112,334        834,250  
January 31, 2024
      0.350        1,343,856        —        —        (1,343,856 )      —         —   
January 31, 2024
      0.350        1,381,012        —        (460,338 )      (662,610 )      258,064        —   
November 22, 2024
      0.305        —         2,700,000        —        —        2,700,000        —   
November 22, 2024
      0.305        —         3,600,000        —        —        3,600,000        —   
November 22, 2024
      0.305        —         3,200,000        —        —        3,200,000        —   
December 5, 2024
      0.310        —         1,700,000        —        —        1,700,000        —   
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
Total
      
 
13,870,535
 
   
 
11,200,000
 
   
 
(6,827,005
) 
  
 
(2,006,466
) 
  
 
16,237,064
 
   
 
834,250
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
     
 
 
  
Fiscal year ended June 30, 2024
 
Grant date
   
Fair
Value
     
Balance at start

of the fiscal
year Number
     
Granted
during the
fiscal year
Number
     
Exercised
during the

fiscal year
Number
    
Lapsed during
the fiscal year
Number
     
Balance at

end of the
fiscal year
Number
     
Vested and
exercisable at end
of the fiscal year
Number
  
October 1, 2021
      0.550        17,699        —         (17,699 )      —         —         —   
November 26, 2021
      0.490        3,600,000        —         —        —         3,600,000        1,200,000  
November 26, 2021
      0.490        4,500,000        —         —        —         4,500,000        1,500,000  
November 26, 2021
      0.490        2,900,000        —         (966,667 )      —         1,933,333        —   
December 16, 2022
      0.330        1,112,334        —         —        —         1,112,334        556,167  
January 31, 2024
      0.350        —         1,343,856        —        —         1,343,856        —   
January 31, 2024
      0.350        —         1,381,012        —        —         1,381,012        —   
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
      
 
12,130,033
 
   
 
2,724,868
 
   
 
(984,366
) 
  
 
— 
 
   
 
13,870,535
 
   
 
3,256,167
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Summary of STI Performance Rights Granted
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2026 included:
 
Grant date
    October 13, 2025  
Share price at grant date
    $ 0.290  
Expected price volatility of the Company’s shares
      64 % 
Expected dividend yield
      Nil  
Risk-free interest rate
      3.71 % 
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2025 included:
 
Grant date
    December 5, 2024     November 22, 2024  
Share price at grant date
    $ 0.31     $ 0.305  
Expected price volatility of the Company’s shares
      63 %      63 % 
Expected dividend yield
      Nil       Nil  
Risk-free interest rate
      3.88 %      4.2 % 
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2024 included:
 
Grant date
    June 30, 2024*     January 31, 2024  
Share price at grant date
    $ 0.295     $ 0.35  
Expected price volatility of the Company’s shares
      62 %      58 % 
Expected dividend yield
      Nil       Nil  
Risk-free interest rate
      4.19 %      3.68 % 
 
*
3,147,952 performance rights due to vest on October 1, 2024, 3,147,952 performance rights due to vest on October 1, 2025 and 447,952 performance rights due to vest on October 1, 2026 have not met the definition of grant date under AASB 2 (IFRS 2) - Share Based payments. Accordingly, the share-based expense recognized was using an estimate of the grant date fair value at June 30, 2024. The value will be re-assessed at each reporting date until grant date has been identified. For all tranches, the vesting conditions consist of service-based vesting conditions subject to certain defined corporate Key Performance Indicators (KPIs). The performance rights will expire, if not exercised, five years from the date of issue. There are no outstanding options under EIP at the beginning of the financial year 2024 and no option was granted during the year ended June 30, 2024.
Directors Incentive Plan [member] | Performance rights [member]  
Statements [Line Items]  
Summaries of Performance Rights Granted
Fiscal year ended June 30, 2026
 
2026
Grant date
    Type of
Performance
right granted		      Fair
Value*		      Balance at
start of the
fiscal year
Number		      Granted
during the
fiscal year
Number		      Exercised
during the
fiscal year
Number		     Lapsed
during the
fiscal year
Number		      Balance at
end of the
fiscal year
Number		      Vested and
exercisable at
end of the
fiscal year
Number		  
November 23, 2022
      Director rights        0.310        777,778        —         (388,889 )      —         388,889        —   
October 24, 2023
      Director rights        0.320        100,000        —         (50,000 )      —         50,000        —   
October 24, 2023
      Director rights        0.320        333,334        —         (166,667 )      —         166,667        —   
November 27, 2025
      Director rights        0.285        —         1,573,646        (250,000 )      —         1,323,646        —   
November 27, 2025
      Director rights        0.285        —         2,058,631        —        —         2,058,631        —   
November 27, 2025
      Director rights        0.285        —         707,232        —        —         707,232        —   
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
            1,211,112        4,339,509        (855,556 )      —         4,695,065        —   
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
The weighted average share price on the exercising date during the financial year 2026 is $0.26.
 
 
Fiscal year ended June 30, 2025
 
2025
Grant date
   
Type of
Performance
right granted
     
Fair
Value*
     
Balance at
start of the
fiscal year
Number
     
Granted
during the
fiscal year
Number
     
Exercised
during the
fiscal year
Number
    
Lapsed
during the
fiscal year
Number
     
Balance at
end of the
fiscal year
Number
     
Vested and

exercisable at
end of the
fiscal year
Number
  
November 23, 2022
      Director rights        0.310        1,166,667        —         (388,889 )      —         777,778        —   
December 1, 2021
      Director rights        0.490        226,414        —         (226,414 )      —         —         —   
October 24, 2023
      Director rights        0.320        178,356        —         (78,356 )      —         100,000        —   
October 24, 2023
      Director rights        0.320        589,955        —         (256,621 )      —         333,334        —   
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
         
 
2,161,392
 
   
 
— 
 
   
 
(950,280
) 
  
 
— 
 
   
 
1,211,112
 
   
 
— 
 
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
The weighted average share price on the exercising date during the financial year 2025 is $0.332.
Fiscal year ended June 30, 2024
 
2024
Grant date
   
Type of
Performance
right granted
     
Fair
Value*
     
Balance at
start of the
fiscal year
Number
     
Granted
during
the fiscal
year
Number
     
Exercised
during the
fiscal year
Number
    
Lapsed
during the
fiscal year
Number
     
Balance at
end of the
fiscal year
Number
     
Vested and
exercisable at
end of the
fiscal year
Number
  
November 1, 2019
      Director rights        0.280        500,000        —         (500,000 )      —         —         —   
November 23, 2022
      Director rights        0.310        1,166,667        —         —         —         1,166,667        —   
December 1, 2021
      Director rights        0.490        226,414        —         —        —         226,414        113,207   
October 24, 2023
      Director rights        0.320        —         178,356        —        —         178,356        28,356  
October 24, 2023
      Director rights        0.320        —         589,955        —        —         589,955        89,954   
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
         
 
1,893,081
 
   
 
768,311
 
   
 
(500,000
) 
  
 
— 
 
   
 
2,161,392
 
   
 
231,517 
 
        
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
The weighted average share price on the exercising date during the financial year 2024 is $0.285.
Summary of STI Performance Rights Granted
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2026 included:
 
Grant date
    November 27, 2025  
Share price at grant date
    $  0.285  
Expected price volatility of the Company’s shares
      62 % 
Expected dividend yield
      Nil  
Risk-free interest rate
      4.05 % 
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2024 included:
 
Grant date
    June 30, 2024*     October 24, 2023  
Share price at grant date
    $ 0.295     $ 0.32  
Expected price volatility of the Company’s shares
      62 %      56 % 
Expected dividend yield
      Nil       Nil  
Risk-free interest rate
      4.11 %      4.3 % 
 
*
Director performance rights granted during the year ended June 30, 2024 have not met the definition of grant date under AASB 2 (IFRS 2) - Share Based payments. Accordingly, the share-based expense recognized was using an estimate of the grant date fair value at June 30, 2024. The value will be re-assessed at the next reporting date as the grant date will be the 2024 AGM date.
Ridgeback Capital Investments and Trout Group LLC. [member] | Stock Option 1 [member]  
Statements [Line Items]  
Summaries of Options Granted
Set out below is a summary of the options granted to both parties:
 
             Balance at      Granted      Exercised     Forfeited      Balance at      Vested and
exercisable		  
             start of the      during the      during the     during the      end of the      at end of the  
2026       Exercise    fiscal year      fiscal year      fiscal year     fiscal year      fiscal year      fiscal year  
Grant date
  
Expiry date
  
price
    Number      Number      Number     Number      Number      Number  
July 31, 2015
   August 4, 2025   0.24      847,600        —         (847,600 )      —         —         —   
      
 
 
     
 
 
     
 
 
    
 
 
     
 
 
     
 
 
  
Total
          847,600        —         (847,600 )      —         —         —